Evidence map›Paper›PMID 42298668›Full record

ArticleJournal of hematology & oncology2026

Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting.

Yagya Ahlawat, Heng Jiang, Delong Liu

Abstract readConference ProceedingsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yagya AhlawatDivision of Hematology and Oncology, Westchester Medical Center, New York Medical College, Valhalla, NY, 10595, USA.
Heng JiangDepartment of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY, 10595, USA.
Delong LiuDivision of Hematology and Oncology, Westchester Medical Center, New York Medical College, Valhalla, NY, 10595, USA. delong_liu@nymc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Luspatercept, an erythroid maturation agent, and imetelstat, a first-in-class telomerase inhibitor, have expanded the therapeutic landscape for patients with myelodysplastic neoplasms (MDS). Recent data presented at the 2025 American Society of Hematology (ASH) Annual Meeting further clarify their evolving clinical roles. New analyses evaluated the real-world use of luspatercept in patients with lower-risk MDS (LR-MDS), while additional studies characterized the efficacy and outcomes associated with imetelstat in transfusion-dependent (TD) LR-MDS and in advanced MDS or acute myeloid leukemia following hypomethylating agent failure. We summarized the latest updates on luspatercept and imetelstat for MDS from the 2025 ASH Annual Meeting.

Indexed as

Activin Receptors, Type IIImmunoglobulin Fc FragmentsMyelodysplastic SyndromesRecombinant Fusion ProteinsHumansTelomeraseActivin Receptors, Type IIImmunoglobulin Fc FragmentsluspaterceptRecombinant Fusion ProteinsTelomeraseImetelstatLuspaterceptMyelodysplastic neoplasmsTelomerase inhibitor

Identifiers

PMID42298668
PMCPMC13267412

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.